Form 4: Tempest Therapeutics Director Acquires Stock Options

Christine Pellizzari, a director at Tempest Therapeutics, acquired stock options for 16,000 shares on June 13, 2024.

Summary

• Christine Pellizzari, a director of Tempest Therapeutics, Inc. (TPST), filed a Form 4 on June 14, 2024.
• The form reports a transaction that occurred on June 13, 2024, where Pellizzari acquired stock options for 16,000 shares of common stock at an exercise price of $3.03.
• These options vest fully on the earlier of June 13, 2025, or the date of the Issuer's 2025 annual stockholder meeting, contingent upon continuous service.
• Following the reported transaction, Pellizzari directly owns derivative securities for 16,000 shares.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Form 4) detailing a director's acquisition of stock options. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's securities. This provides transparency to the market regarding insider activity.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates